Edgar Filing: NOVAVAX INC - Form 8-K

NOVAVAX INC Form 8-K November 10, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 10, 2008 NOVAVAX, INC.

(Exact name of Registrant as specified in its charter)

Delaware 0-26770 22-2816046

(State or other jurisdiction of (Commission File Number) (I.R.S. Employer Identification

incorporation or organization) No.)

9920 Belward Campus Drive

Rockville, Maryland 20850 (Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (240) 268-2000 (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: NOVAVAX INC - Form 8-K

Item 2.02. Results of Operations and Financial Condition

On November 10, 2008, Novavax, Inc. (the Company) issued a press release announcing its financial results for the third quarter ended September 30, 2008 and will conduct a previously announced, publicly available conference call to discuss those results as well as to provide an update on the status of the Company s business operations.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8K and Exhibit 99.1 attached hereto shall not be deemed filed for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits Description

99.1 Press release issued by Novavax, Inc., dated November 10, 2008

Edgar Filing: NOVAVAX INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

Novavax, Inc. (Registrant)

November 10, 2008 By: Name: /s/ Len Stigliano

Title: Vice President, Treasurer and

Chief Financial Officer